Merus N.V.·Healthcare

YLÖJÄRVI, Finland--(BUSINESS WIRE)--Merus Power Oyj has signed a battery energy storage deal worth approximately 13 million euros with Neve Oy.

Federated Hermes Inc. lessened its position in Merus N.V. (NASDAQ: MRUS) by 18.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,249,162 shares of the biotechnology company's stock after selling 279,425 shares during the period. Federated Hermes Inc. owned
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.